Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × HER2-positive Early Breast Cancer × pertuzumab × Clear all

Phase

Phase 3 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 71 Neoplasms 5 HER2-positive Breast Cancer 5 Carcinoma, Non-Small-Cell Lung 4 Triple Negative Breast Neoplasms 3 Prostatic Neoplasms 3 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Stomach Neoplasms 2 Pathologic Complete Response 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Locally Advanced Breast Cancer 2 Biliary Tract Neoplasms 2 Anatomic Stage I Breast Cancer AJCC v8 2 Urinary Bladder Neoplasms 1 Salivary Gland Neoplasms 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Neuroblastoma 1 Neoplastic Cells, Circulating 1 Neoplasms, Unknown Primary 1 Multiple Endocrine Neoplasia 1 Metastatic HER2-Positive Breast Cancer 1 Metastatic Breast Cancer With a Isolated Brain Progression 1 Malignant Solid Neoplasm 1 Lung Neoplasms 1 Inflammatory Breast Neoplasms 1 Her2-Positive Breast Cancer 1

Interventions

pyrotinib 1 pertuzumab 1 Trastuzumab 1 Taxes 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07340398 2026-01-21

TAYLOR

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Recruiting

HER2-positive Early Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡